These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 17686547)

  • 21. Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis.
    Zou B; Lee VHF; Yan H
    BMC Bioinformatics; 2018 Mar; 19(1):88. PubMed ID: 29514601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adenocarcinoma of the lung with rare insertion mutation in EGFR exon 19 that had partial response to gefitinib: a case report.
    Kozlov V; Karpov I; Kovalenko S; Shamanin V
    Exp Oncol; 2017 Jul; 39(2):155-156. PubMed ID: 29483495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler.
    Sasaki H; Endo K; Konishi A; Takada M; Kawahara M; Iuchi K; Matsumura A; Okumura M; Tanaka H; Kawaguchi T; Shimizu T; Takeuchi H; Yano M; Fukai I; Fujii Y
    Clin Cancer Res; 2005 Apr; 11(8):2924-9. PubMed ID: 15837743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients.
    Wang Z; Wu YL; Zhang GC; Zhou Q; Xu CR; Guo AL
    Onkologie; 2008 Apr; 31(4):174-8. PubMed ID: 18418018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.
    Taron M; Ichinose Y; Rosell R; Mok T; Massuti B; Zamora L; Mate JL; Manegold C; Ono M; Queralt C; Jahan T; Sanchez JJ; Sanchez-Ronco M; Hsue V; Jablons D; Sanchez JM; Moran T
    Clin Cancer Res; 2005 Aug; 11(16):5878-85. PubMed ID: 16115929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.
    Bai H; Mao L; Wang HS; Zhao J; Yang L; An TT; Wang X; Duan CJ; Wu NM; Guo ZQ; Liu YX; Liu HN; Wang YY; Wang J
    J Clin Oncol; 2009 Jun; 27(16):2653-9. PubMed ID: 19414683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.
    Won YW; Han JY; Lee GK; Park SY; Lim KY; Yoon KA; Yun T; Kim HT; Lee JS
    J Clin Pathol; 2011 Nov; 64(11):947-52. PubMed ID: 21725039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Epidermal growth factor receptor mutation in Chinese patients with non-small cell lung cancer].
    Pan ZK; Zhang L; Zhang X; Wang X; Li N; Xu F; Chang JH; Guan ZZ
    Ai Zheng; 2005 Aug; 24(8):919-23. PubMed ID: 16086866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.
    Bean J; Riely GJ; Balak M; Marks JL; Ladanyi M; Miller VA; Pao W
    Clin Cancer Res; 2008 Nov; 14(22):7519-25. PubMed ID: 19010870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients.
    Han SW; Kim TY; Lee KH; Hwang PG; Jeon YK; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Heo DS; Bang YJ
    Lung Cancer; 2006 Nov; 54(2):201-7. PubMed ID: 16956694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort.
    Varella-Garcia M; Mitsudomi T; Yatabe Y; Kosaka T; Nakajima E; Xavier AC; Skokan M; Zeng C; Franklin WA; Bunn PA; Hirsch FR
    J Thorac Oncol; 2009 Mar; 4(3):318-25. PubMed ID: 19247083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation.
    Fukuhara T; Maemondo M; Inoue A; Kobayashi K; Sugawara S; Oizumi S; Isobe H; Gemma A; Harada M; Yoshizawa H; Kinoshita I; Fujita Y; Saijo Y; Hagiwara K; Morita S; Nukiwa T
    Lung Cancer; 2015 May; 88(2):181-6. PubMed ID: 25726043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes.
    Locatelli-Sanchez M; Couraud S; Arpin D; Riou R; Bringuier PP; Souquet PJ
    Lung; 2013 Oct; 191(5):491-9. PubMed ID: 23749122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
    Li J; Qu L; Wei X; Gao H; Wang W; Qin H; Tang C; Guo W; Wang H; Liu X
    Zhongguo Fei Ai Za Zhi; 2012 May; 15(5):299-304. PubMed ID: 22613337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).
    Martínez-Navarro EM; Rebollo J; González-Manzano R; Sureda M; Evgenyeva E; Valenzuela B; Fernández FJ; Forteza J; Brugarolas A
    Clin Transl Oncol; 2011 Nov; 13(11):812-8. PubMed ID: 22082647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.
    He M; Capelletti M; Nafa K; Yun CH; Arcila ME; Miller VA; Ginsberg MS; Zhao B; Kris MG; Eck MJ; Jänne PA; Ladanyi M; Oxnard GR
    Clin Cancer Res; 2012 Mar; 18(6):1790-7. PubMed ID: 22190593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Relationship between EGFR and K-ras mutations and clinicopathological characteristics and response to erlotinib treatment in 301 Chinese patients with non-small cell lung cancer].
    Sun LN; Luan HL; Zang FL; Wang M; Dong N; Guo Y; Sun BC; Zhan ZL
    Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):667-70. PubMed ID: 21122380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low plasma concentration of gefitinib in patients with EGFR exon 21 L858R point mutations shortens progression-free survival.
    Okuda Y; Sato K; Sudo K; Hasegawa Y; Asano M; Miura H; Takeda M; Sano M; Watanabe H; Kobayashi H; Niioka T; Miura M; Ito H
    Cancer Chemother Pharmacol; 2017 May; 79(5):1013-1020. PubMed ID: 28391354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidermal growth factor receptor mutations and the clinical outcome in male smokers with squamous cell carcinoma of lung.
    Park SH; Ha SY; Lee JI; Lee H; Sim H; Kim YS; Hong J; Park J; Cho EK; Shin DB; Lee JH
    J Korean Med Sci; 2009 Jun; 24(3):448-52. PubMed ID: 19543508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.